Efforts to develop stroke treatments have been met with limited success despite an intense need to produce novel treatments. The failed translation of many of these therapies in clinical trials has lead to a close examination of the therapeutic development process. One of the major factors believed to be limiting effective screening of these treatments is the absence of an animal model more predictive of human responses to treatments. See our publication in Experimental & Translational Stroke Medicine for more.

Posted in: